To the best of our knowledge, only TP53 and IGFBP2 have been investigated for their diagnostic potential as autoantibodies in pancreatic cancer [44, 45], while the diagnostic application of TAAbs targeting other identified TAAs has not been reported in the literature to date. This evidence concerns the gene IGFBP2 and familial pancreatic carcinoma.